{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Delles C"],"funding":["Oulun Yliopisto","Novo Nordisk Foundation","The Engineering and Physical Sciences Research Council","University of Bristol","Sigrid Juselius Foundation","European Commission under the Health Cooperation Work Programme of the 7th Framework Programme","Academy of Finland","European Federation of Pharmaceutical Industries Associations (EFPIA)","The Medical Research Council","European Medical Information Framework (EMIF)","Medical Research Council","Finnish Foundation","Innovative Medicines Initiative Joint Undertaking","Novo Nordisk Fonden"],"pagination":["663-673"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5947152"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(4)"],"pubmed_abstract":["<h4>Aims</h4>We investigated the association between quantified metabolite, lipid and lipoprotein measures and incident heart failure hospitalisation (HFH) in the elderly, and examined whether circulating metabolic measures improve HFH prediction.<h4>Methods and results</h4>Overall, 80 metabolic measures from the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) trial were measured by proton nuclear magnetic resonance spectroscopy (n = 5341; 182 HFH events during 2.7-year follow-up). We repeated the work in FINRISK 1997 (n = 7330; 133 HFH events during 5-year follow-up). In PROSPER, the circulating concentrations of 13 metabolic measures were found to be significantly different in those who were later hospitalised for heart failure after correction for multiple comparisons."],"journal":["European journal of heart failure"],"pubmed_title":["Nuclear magnetic resonance-based metabolomics identifies phenylalanine as a novel predictor of incident heart failure hospitalisation: results from PROSPER and FINRISK 1997."],"pmcid":["PMC5947152"],"funding_grant_id":["305507","115372","MC_UU_1201/1","294834","MR/N005813/1","NNF15OC0015998"],"pubmed_authors":["Delles C","Ford I","Kangas A","Boachie C","Jukema JW","Zannad F","Salomaa V","Wurtz P","Sattar N","McConnachie A","Rankin NJ","Soininen P","Mooijaart SP","Ala-Korpela M","Havulinna AS","Welsh P","Trompet S"],"additional_accession":[]},"is_claimable":false,"name":"Nuclear magnetic resonance-based metabolomics identifies phenylalanine as a novel predictor of incident heart failure hospitalisation: results from PROSPER and FINRISK 1997.","description":"<h4>Aims</h4>We investigated the association between quantified metabolite, lipid and lipoprotein measures and incident heart failure hospitalisation (HFH) in the elderly, and examined whether circulating metabolic measures improve HFH prediction.<h4>Methods and results</h4>Overall, 80 metabolic measures from the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) trial were measured by proton nuclear magnetic resonance spectroscopy (n = 5341; 182 HFH events during 2.7-year follow-up). We repeated the work in FINRISK 1997 (n = 7330; 133 HFH events during 5-year follow-up). In PROSPER, the circulating concentrations of 13 metabolic measures were found to be significantly different in those who were later hospitalised for heart failure after correction for multiple comparisons.","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Apr","modification":"2025-04-04T19:25:51.788Z","creation":"2019-03-26T23:37:44Z"},"accession":"S-EPMC5947152","cross_references":{"pubmed":["29226610"],"doi":["10.1002/ejhf.1076"]}}